Xerox Reports Mixed Q2 Results; Inflation & Supply Woes Hit Margins
Xerox Holdings Corp (NASDAQ:XRX) reported a second-quarter FY22 sales decline of 2.6% year-on-year to $1.75 billion, missing the consensus of $1.79 billion.…
‘CHIPS: Senate has cleared 60 vote threshold to end debate on semiconductor bill. Smooth sailing in Senate from here’ -Bloomberg Reporter
https://twitter.com/elwasson/status/1551956507809312770https://twitter.com/elwasson/status/1551956507809312770
Meta, Google, Pinterest Hit With Price Target Cuts Ahead Of Q2 Earnings: Here’s Why
As social-media stocks gear up to release their quarterly reports over the week and the next, an analyst at KeyBanc Capital Markets lowered his estimates and price targets for the big players in the space.
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
SomaLogic Acquires DNA Nanotechnology Provider For $35M
SomaLogic Inc (NASDAQ:SLGC) has agreed to acquire Palamedrix Inc for $14 million in cash and $21 million in SomaLogic common stock. Up…
Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) has reported results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development…
Virax Biolabs Introduces Monkeypox And Varicella-Zoster Viruses Real-Time PCR Detection Kit
Virax Biolabs Group Limited (“Virax” or the “Company”) (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched
Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol
- ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023
Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)